

Active studies

Title	Phase	Tumortype	Line of Therapy	Study Information	Register
First-line immunotherapy using Wilms' tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma (MESODEC)	I/II	MPM	1L	<ul style="list-style-type: none"> • Epitheloid mesothelioma • Q3W: Pemetrexed + Cisplatinum + DC vaccination • Ongoing DC vaccination Q4W 	NCT02649829
ALK, ROS1 and MET testing in cell-free RNA and DNA for improved precision oncology guided management of non-small cell lung cancer patients (LONG 18-05)	NA	NSCLC ROS, ALK and MET mutations	NA	The overall goal of the study is to assess the analytical performance to identify relevant mutations in ALK, ROS1 and MET in plasma from NSCLC patient. Doing so, we want to provide a rationale for a cost-effective testing procedure for future Belgian NSCLC patients for sensitive and straightforward mutation testing in easily accessible blood samples.	/
A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	III	NSCLC RET +	1L	<ul style="list-style-type: none"> • Arm A BID: LOXO-292 (Selpercatinib) • Arm B Q3W: pemetrexed + carbo- or cisplatin +/- pembrolizumab → possibility to crossover to Arm A after progression 	NCT04194944

<p>An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)</p>	<p>I/II</p>	<p>NSCLC PD-L1 ≥ 50%</p>	<p>1L</p>	<ul style="list-style-type: none"> • SoC (+/- anti-PD-1) + PDC*lung01 (Q1W) 	<p>NCT03970746</p>
<p>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)</p>	<p>II</p>	<p>NSCLC Stage IIIB-IV non-squamous</p>	<p>1L</p>	<ul style="list-style-type: none"> • Arm A: <ul style="list-style-type: none"> ○ Induction 4x Q3W: Tiragolumab + Atezolizumab + Pemetrexed + Carboplatin/Cisplatin ○ Maintenance: Q3W: Tiragolumab + Atezolizumab + Pemetrexed • Arm B: <ul style="list-style-type: none"> ○ Induction 4x Q3W: Placebo + Pembrolizumab + Pemetrexed + Carboplatin/Cisplatin ○ Maintenance: Q3W: Placebo + Pembrolizumab + Pemetrexed 	<p>NCT04619797</p>
<p>A multicenter non-interventional cohort study to evaluate the real-world clinical management and outcomes of patients diagnosed with ALK-positive advanced NSCLC treated with Alectinib (REALEC)</p>	<p>NA</p>	<p>NSCLC ALK+</p>	<p>1L</p>	<ul style="list-style-type: none"> • Observational study • SOC: Alectinib (BID) 	<p>NCT04764188</p>

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer (M14-239)	II	NSCLC Stage III, IV c-Met+	2L or 3L	<ul style="list-style-type: none"> • Telisotuzumab Vedotin (Q2W) 	NCT03539536
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8)	III	NSCLC Stage III Unresectable PD-L1 \geq 1%	maintenance treatment after cCRT	<ul style="list-style-type: none"> • Arm A: durvalumab + domvanalimab (Q4W) • Arm B: durvalumab + placebo (Q4W) 	NCT05211895
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS \geq 50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)	III	NSCLC Stage IIIB, IIIC, IV PD-L1 \geq 50%	1L	<ul style="list-style-type: none"> • Arm 1: Dato-DXd + pembrolizumab (Q3W) • Arm 2: Pembrolizumab (Q3W) 	NCT05215340

